Condensed Consolidated Statements of Income - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2017	Mar. 31, 2016
Condensed Consolidated Statements of Income
Net sales	$ 7,715,955	$ 7,408,990	$ 24,592,043	$ 22,281,107
Cost of sales	5,014,175	4,922,570	16,022,269	14,606,877
Gross profit	2,701,780	2,486,420	8,569,774	7,674,230
Selling, general, and administrative expenses	3,153,257	2,620,238	8,768,851	7,445,023
Research and development expenses	230,594	249,995	818,954	769,223
Operating loss	(682,071)	(383,813)	(1,018,031)	(540,016)
Other income (expense):
Interest income	124	175	488	2,658
Interest expense	(74,992)	(71,690)	(198,084)	(229,207)
Other income, net	2,208	4,640	79,943	9,635
Net other expense	(72,660)	(66,875)	(117,653)	(216,914)
Loss before income taxes	(754,731)	(450,688)	(1,135,684)	(756,930)
Income tax (provision) benefit
Net loss	(754,731)	(450,688)	(1,135,684)	(756,930)
Deemed dividend on 8% convertible preferred stock			(375,858)
8% Convertible preferred stock dividend	(93,979)	(80,500)	(271,756)	(241,500)
Net loss attributable to common stockholders	$ (848,710)	$ (531,188)	$ (1,783,298)	$ (998,430)
Basic and diluted net loss per common share	$ (0.28)	$ (0.19)	$ (0.61)	$ (0.37)
Weighted-average common shares outstanding:
Basic	3,022,443	2,731,282	2,914,229	2,681,493
Diluted	3,022,443	2,731,282	2,914,229	2,681,493